This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, 522, 524, 529, and 558

[Docket No. FDA–2015–N–0002]

New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor’s Name; Change of Sponsor’s Address

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendments.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during January and February 2015. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect several non-substantive changes. These technical amendments are being made to improve the accuracy of the regulations.

DATES: This rule is effective April 8, 2015, except for the amendment to 21 CFR 522.1004, which is effective April 20, 2015.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV–6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–276–9019, george.haibel@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during January and February 2015, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm. Marketing exclusivity and patent information may be accessed in FDA’s publication, Approved Animal Drug Products Online (Green Book) at: http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm.

<table>
<thead>
<tr>
<th>NADA/ANADA</th>
<th>Sponsor</th>
<th>New animal drug product name</th>
<th>Action</th>
<th>21 CFR sections</th>
<th>FOIA summary</th>
<th>NEPA review</th>
</tr>
</thead>
</table>
### Table 1—Original and Supplemental NADAs and ANADAs Approved During January and February 2015—Continued

<table>
<thead>
<tr>
<th>NADA/ANADA</th>
<th>Sponsor</th>
<th>New animal drug product name</th>
<th>Action</th>
<th>21 CFR sections</th>
<th>FOIA summary</th>
<th>NEPA review</th>
</tr>
</thead>
<tbody>
<tr>
<td>141–280</td>
<td>Intervet, Inc., 556 Morris Ave., Summit, NJ 07901.</td>
<td>ZILMAX (zilpaterol hydrochloride) plus RUMENSIN (monensin) plus TYLAN (tylosin phosphate) plus MGA (melengestrol acetate) Type A medicated articles.</td>
<td>Supplemental approval to provide for component feeding of combination drug Type C medicated feeds to heifers fed in confinement for slaughter.</td>
<td>558.665</td>
<td>yes .................</td>
<td>CE 15</td>
</tr>
<tr>
<td>141–406</td>
<td>Merial, Inc., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096–4640.</td>
<td>NEXGARD (afoxolaner) Chewable Tablets.</td>
<td>Supplemental approval for the treatment and control of an additional tick species in dogs and puppies.</td>
<td>520.43</td>
<td>yes .................</td>
<td>CE 1 2</td>
</tr>
</tbody>
</table>

1 The Agency has determined that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not have a significant effect on the human environment.

2 CE granted under 21 CFR 25.33(d)(1).

3 CE granted under 21 CFR 25.33(a)(1).

4 This application is affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209”, December 2013.

5 CE granted under 21 CFR 25.33(a)(2).

In addition during January and February 2015, ownership of, and all rights and interest in, the following approved applications have been transferred as follows:

<table>
<thead>
<tr>
<th>NADA/ANADA</th>
<th>Previous sponsor</th>
<th>New sponsor</th>
<th>New animal drug product name</th>
<th>21 CFR Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>141–098</td>
<td>Abbott Laboratories, North Chicago, IL 60064.</td>
<td>Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007.</td>
<td>PROPOFLO (propofol) Injectable Suspension.</td>
<td>522.2005</td>
</tr>
<tr>
<td>141–103</td>
<td>Abbott Laboratories, North Chicago, IL 60064.</td>
<td>Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007.</td>
<td>SEVOFLO (sevoflurane) Inhalation Anesthetic.</td>
<td>529.2150</td>
</tr>
<tr>
<td>141–346</td>
<td>Abbott Laboratories, North Chicago, IL 60064.</td>
<td>Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007.</td>
<td>OROCAM (meloxicam) Oral Spray.</td>
<td>529.1350</td>
</tr>
<tr>
<td>141–434</td>
<td>Abbott Laboratories, North Chicago, IL 60064.</td>
<td>Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007.</td>
<td>SIMBADOL (buprenorphine) Injectable Solution.</td>
<td>522.230</td>
</tr>
<tr>
<td>200–070</td>
<td>Abbott Laboratories, North Chicago, IL 60064.</td>
<td>Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007.</td>
<td>ISOFLO (isoflurane) Inhalation Anesthetic.</td>
<td>529.1186</td>
</tr>
<tr>
<td>048–480</td>
<td>ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305–3115.</td>
<td>Pharmgate LLC, 161 North Franklin Turnpike, suite 2C, Ramsey, NJ 07446.</td>
<td>CHLORATET 90 and 100 (chloramphenicol) Type A medicated articles.</td>
<td>558.128</td>
</tr>
<tr>
<td>141–067</td>
<td>OPK Biotech, LLC, 11 and 39 Hurley St., Cambridge, MA.</td>
<td>Hemoglobin Oxygen Therapeutics, LLC, 674 Souder Rd., Souderton, PA 18964.</td>
<td>OXYGLOBIN (hemoglobin glutamer-200 (bovine)).</td>
<td>522.1125</td>
</tr>
</tbody>
</table>
At this time, the regulations are being amended to reflect these changes of sponsorship.

In addition, Paladin Labs (USA), Inc., 160 Greentree Dr., Suite 101, Dover, DE 19904 has requested that FDA withdraw approval of NADA 141–075 for ANTIZOL–VET (fomepizole) Injection. Elsewhere in this issue of the Federal Register, FDA gave notice that approval of NADA 141–075, and all supplements and amendments thereto, is withdrawn, effective April 20, 2015. As provided in the regulatory text of this document, the animal drug regulations are being amended to reflect this voluntary withdrawal of approval.

Following these changes of sponsorship and withdrawal of approval, Hemoglobin Oxygen Therapeutics, LLC is now the sponsor of an approved application, while OPK Biotech, LLC and Paladin Labs (USA), Inc., are no longer the sponsor of an approved application. Also, Merial, Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096–4640, has informed FDA that it has changed its name to Merial, Inc., and Intervet, Inc., 556 Morris Ave., Summit, NJ 07901, has informed FDA that it has changed its address to 2 Giralda Farms, Madison, NJ 07940. Accordingly, §510.600 (21 CFR 510.600) is being amended to reflect these changes.

In addition, FDA is amending the tables in §510.600(c) to remove listings for International Nutrition, Inc.; NutriBasics Co.; Seeco Inc.; Southern Micro-Blenders, Inc.; and Wellmark International because these firms are no longer the sponsor of an approved application. These technical amendments are being made to improve the accuracy of the regulations. This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects
21 CFR Part 510
Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Parts 520, 522, 524, and 529
Animal drugs.

21 CFR Part 558
Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, 529, and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:


2. Amend §510.600 as follows:

■ a. In the table in paragraph (c)(1), remove the entries for “Contemporary Products, Inc.”, “International Nutrition, Inc.”, “NutriBasics Co.”, “OPK Biotech, LLC”, “Paladin Labs (USA), Inc.”, “Seeco Inc.”, “Southern Micro-Blenders, Inc.”, and “Wellmark International”;

■ b. In the table in paragraph (c)(1), revise the entries for “Intervet, Inc.” and “Merial Ltd.”; and add an entry, in alphabetical order, for “Hemoglobin Oxygen Therapeutics, LLC”;

■ c. In the table in paragraph (c)(2), remove the entries for “011536”, “043733”, “046129”, and “055462”;

■ d. In the table in paragraph (c)(2), revise the entries for “011536”, “043733”, “046129”, and “055462”; and

■ e. In the table to dogs weighing 23 to 110 lb.

The additions and revisions read as follows:

§510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *

(a) Specifications. Each chewable tablet contains 7.5 or 37.5 milligrams (mg) imidacloprid.

(b) Sponsor. See No. 000859 in part 520 of this chapter.

(c) Conditions of use in dogs—(1)

Amount. Administer daily one 7.5-mg chewable tablet to dogs weighing 4 to 22 pounds (lb) or one 37.5-mg chewable table to dogs weighing 23 to 110 lb.

(2) Indications for use. Kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 8 weeks of age and older, weighing 4 lb of body weight or greater, for 1 month.

* * * * *

§520.441 [Amended]

5. In §520.441, in paragraph (b)(4), remove “012286” and in its place add “096294”.

6. Add §520.1156 to read as follows:

§520.1156 Imidacloprid.

(a) Specifications. Each chewable tablet contains 7.5 or 37.5 milligrams (mg) imidacloprid.

(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1)

Amount. Administer daily one 7.5-mg chewable tablet to dogs weighing 4 to 22 pounds (lb) or one 37.5-mg chewable table to dogs weighing 23 to 110 lb.

(2) Indications for use. Kills adult fleas and is indicated for the treatment of fleas infestations on dogs and puppies 10 weeks of age and older and weighing 4 lb or greater.

(3) Limitations. Do not give to puppies younger than 10 weeks of age or to dogs weighing less than 4 lb. Do not give more than one tablet a day.
§ 520.1443 [Amended]
7. In § 520.1443, in paragraph (b), remove “058198” and in its place add “051311”.

§ 520.1447 [Amended]
8. In § 520.1447, in paragraph (b), remove “058198” and in its place add “051311”.

9. In § 520.1510, in paragraph (d)(1)(ii)(B), remove “§ 520.1446(d)(1)” of this chapter and in its place add “§ 520.1443(d)(1)”.

10. In § 520.2158, in paragraph (b), remove “058198” and in its place add “051311”.

11. The authority citation for 21 CFR part 522 continues to read as follows:


§ 520.1510 Nitenpyram.
* * * * *
(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter:
(1) No. 058198 for use as in paragraphs (d)(1)(i)(A), (d)(1)(ii)(A), and (d)(2) of this section.
(2) No. 051311 for use as in paragraphs (d)(1)(i)(B) and (d)(1)(ii)(B) of this section.
* * * * *

§ 520.2158 [Amended]
10. In § 520.2158, in paragraph (b), remove “Nos. 016592 and 055462” and in its place add “No. 016592”.

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

11. The authority citation for 21 CFR part 522 continues to read as follows:

12. Add § 522.167 to read as follows:

§ 522.167 Betamethasone sodium phosphate and betamethasone acetate.
(a) Specifications. Each milliliter (mL) of suspension contains 6 milligrams (mg) betamethasone (3.15 mg betamethasone sodium phosphate and 2.85 mg betamethasone acetate).
(b) Sponsor. See No. 010797 in § 510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. Administer 1.5 mL (9 mg total betamethasone) per joint by intra-articular injection. May be administered concurrently in up to two joints per horse.

(2) Indications for use. For the control of pain and inflammation associated with osteoarthritis in horses.
(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.230 [Amended]
13. In § 522.230, in paragraph (b), remove “000044” and in its place add “054771”.
14. In § 522.812, add paragraph (b)(3) to read as follows:

§ 522.812 Enrofloxacin.
* * * * *
(b) * * * *
(3) No. 026637 for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section.
* * * * *

§ 522.1004 [Removed]
15. Remove § 522.1004.
16. In § 522.2005, remove paragraph (b)(3); and revise paragraph (b)(2) to read as follows:

§ 522.2005 Propofol.
* * * * *
(b) * *
(2) No. 054771 for use as in paragraph (c) of this section.
* * * * *

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

17. The authority citation for 21 CFR part 524 continues to read as follows:

18. Revise § 524.1044a to read as follows:

§ 524.1044a Gentamicin ophthalmic solution.
(a) Specifications. Each milliliter of solution contains gentamicin sulfate equivalent to 3 milligrams of gentamicin.
(b) Sponsor. See Nos. 000061 and 059399 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs and cats—(1) Amount. Administer 1 or 2 drops into the conjunctival sac 2 to 4 times a day.

(2) Indications for use. For the topical treatment of infections of the conjunctiva caused by susceptible bacteria.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

19. The authority citation for 21 CFR part 529 continues to read as follows:

§ 529.1186 [Amended]
20. In § 529.1186, in paragraph (b), remove “000044” and add “054771,” after “012164,”.

§ 529.1350 [Amended]
21. In § 529.1350, in paragraph (b), remove “000074” and in its place add “054771”.

§ 529.2150 [Amended]
22. In § 529.2150, in paragraph (b), remove “000044” and add “054771,” after “012164,”.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

23. The authority citation for 21 CFR part 558 continues to read as follows:

§ 558.128 [Amended]
24. Amend § 558.128 as follows:
(a) In paragraph (b)(2), remove “No. 012286” and in its place add “No. 069254”;
(b) In paragraph (e)(3)(iv), in the “Limitations” column, remove “012286” and in its place add “069254”; and
(c) In the tables in paragraphs (e)(1), (e)(2), (e)(3), and (e)(4), in the “Sponsor” column, remove “012286,” wherever it occurs.

25. In § 558.665, add paragraph (e)(9) to read as follows:

§ 558.665 Zipatropin.
* * * * *
(e) * * *
<table>
<thead>
<tr>
<th>Zipatarol in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(9) 6.8 to 24 ......</td>
<td>Monensin 10 to 40, plus tyllosin 8 to 10, plus melengestrol acetate to provide 0.25 to 0.5 mg/ head/day.</td>
<td>Heifers fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feed; for prevention and control of coccidiosis due to <em>Eimeria bovis</em> and <em>E. zuernii</em>; and for reduction of incidence of liver abscesses caused by <em>Fusobacterium necrophorum</em> and <em>Arcanobacterium (Actinomyces) pyogenes</em>; and for suppression of estrus (heat).</td>
<td>Feed continuously to heifers during the last 20 to 40 days on feed to provide 60 mg zipatarol hydrochloride per head per day. See §§558.342(d), 558.355(d), and 558.625(c). Monensin and tyllosin as provided by No. 000986; melengestrol acetate as provided by No. 054771 in § 510.600(c) of this chapter. Withdrawal period: 3 days.</td>
<td>000061</td>
</tr>
</tbody>
</table>


Bernadette Dunham,  
Director, Center for Veterinary Medicine.

[FR Doc. 2015–08025 Filed 4–7–15; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

21 CFR Part 522

[Docket No. FDA–2015–N–0002]

Implantation or Injectable Dosage Form New Animal Drugs; Withdrawal of Approval of New Animal Drug Application; Fomepizole

AGENCY: Food and Drug Administration, HHS.

ACTION: Notification of withdrawal.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of a new animal drug application (NADA) for a fomepizole injectable solution used as an antidote for ethylene glycol poisoning in dogs. This action is being taken at the sponsor’s request because this product is no longer manufactured or marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADA 141–075, and all supplements and amendments thereto, is hereby withdrawn.

Elsewhere in this issue of the Federal Register, FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of this application.


Bernadette Dunham,  
Director, Center for Veterinary Medicine.

[FR Doc. 2015–08024 Filed 4–7–15; 8:45 am]
BILLING CODE 4164–01–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Parts 260 and 261


Response to Vacaturs of the Comparable Fuels Rule and the Gasification Rule

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

SUMMARY: The Environmental Protection Agency (EPA) is revising regulations associated with the comparable fuels exclusion and the gasification exclusion, originally issued by EPA under the Resource Conservation and Recovery Act (RCRA). These revisions implement vacaturs ordered by the United States Court of Appeals for the District of Columbia Circuit (D.C. Circuit), on June 27, 2014.

DATES: Effective April 8, 2015.

ADDRESS: EPA has established a docket for this action under Docket ID No. EPA–HQ–RCRA–2015–0118. All documents in the docket are listed in the www.regulations.gov index. Although listed in the index, some information is not publicly available, e.g., Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, is not placed on the internet and will be publicly available only in hard copy form. Publicly available docket materials are available either electronically through www.regulations.gov or in hard copy at the EPA Docket Center, EPA/DC, WIC West Building, Room 3334, 1301 Constitution Ave. NW., Washington, DC. The Public Reading Room is open from 8:30 a.m. to 4:30 p.m. Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is (202) 566–1744 and the telephone number for the RCRA Docket is (202) 566–0270.

FOR FURTHER INFORMATION CONTACT: Office of Resource Conservation and Recovery, Materials Recovery and Waste Management Division, MC 5304P, Environmental Protection Agency, 1200 Pennsylvania Ave. NW., Washington, DC 20460, Tracy Atagi, at (703) 308–8672, (atagi.tracy@epa.gov) or Frank Behan, at (703) 308–8476, behan.frank@epa.gov.

SUPPLEMENTARY INFORMATION:

Preamble Outline

I. General Information  
II. Statutory Authority  
III. Which regulations is EPA removing?  
IV. Background on the Comparable Fuels Rule and the Gasification Rule  
V. When will the final rule become effective?  
VI. State Authorization  
VII. Statutory and Executive Order (EO)  
 Reviews